PayPal (PYPL) downgraded by Mizuho to Neutral with $50 target as X Money platform threatens core business and Q4 earnings disappoint analysts.
Browsing: News
Okta (OKTA) rises 4% after dual upgrades from Barclays and Raymond James, driven by identity security demand and emerging agentic AI opportunities.
MicroStrategy (MSTR) stock fell 2.5% after purchasing 34,164 BTC for $2.54B, marking its third-largest bitcoin buy. Total holdings now exceed 815K BTC.
Northrop Grumman (NOC) reports Q1 earnings Tuesday. Analysts expect $6.05 EPS and $9.76B revenue. Will margin recovery finally materialize?
Marvell (MRVL) achieves record revenue of $8.19B, explores Google AI chip partnership, and refocuses on data center infrastructure.
OpenAI is preparing to launch an advanced AI image generator featuring enhanced realism and diagram capabilities, directly competing with Google’s tools.
Evercore ISI upgrades Arista Networks (ANET) and IBM (IBM) to tactical outperform, expecting both companies to beat Q1 estimates and raise guidance.
Adobe (ADBE) stock rose 1.8% after unveiling CX Enterprise AI platform. Shares still down 30% YTD amid AI disruption concerns despite new partnerships.
Clearmind Medicine (CMND) stock doubled after CMND-100 achieved its primary safety endpoint in Phase I/IIa AUD trial with no serious adverse events reported.
KeyBanc lifts Amazon (AMZN) price target to $325 citing Anthropic’s $30B ARR surge and accelerating AWS AI momentum ahead of April 29 earnings.
Discover the top 5 cloud infrastructure stocks analysts recommend for 2026, including Microsoft, Nvidia, Amazon, Broadcom, and Arista Networks.
Enveric Biosciences (ENVB) soared 160%+ after Trump’s executive order fast-tracking psychedelic drug reviews and pledging $50M for ibogaine PTSD research.
COMPASS Pathways (CMPS) stock jumped 25% after Trump’s executive order on psychedelic research and positive Phase 3 trial results for treatment-resistant depression.
Definium Therapeutics (DFTX) jumped 13% premarket after Trump’s Executive Order supporting psychedelic research. Analysts see 70% upside potential.
Rocket Lab (RKLB) receives $105 price targets from top analysts as insiders sell shares. Mynaric acquisition complete, expanding optical communications.